問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

許雅婷Hsu, Ya-Ting
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

Recruiting Trial

121Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

許雅婷

List

167Cases

2017-11-01 - 2022-06-27

Phase III

A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)

  • Condition/Disease

    Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)

  • Test Drug

    Pembrolizumab; Epacadostat

Participate Sites
6Sites

Terminated6Sites

2017-07-26 - 2020-06-30

Phase III

A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)

  • Condition/Disease

    Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer

  • Test Drug

    Pembrolizumab (MK-3475)

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2020-12-25 - 2025-07-31

Phase III

A randomized, double-blind, placebo-controlled, active-comparator, multicenter, phase 3 study of brentuximab vedotin or placebo in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

  • Condition/Disease

    diffuse large B-cell lymphoma (DLBCL)

  • Test Drug

    Brentuximab Vedotin, Lenalidomide,Rituximab

Participate Sites
7Sites

Recruiting7Sites

2018-08-31 - 2026-05-31

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER

  • Condition/Disease

    Triple-Negative Breast Cancer

  • Test Drug

    Atezolizumab (RO5541267)

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated9Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2021-03-17 - 2025-06-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2019-11-17 - 2021-12-31

Phase III

A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

  • Condition/Disease

    Lower Respiratory Tract Parainfluenza Infection

  • Test Drug

    DAS181

Participate Sites
2Sites

Recruiting2Sites

2019-01-24 - 2020-12-31

Phase III

A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane

  • Condition/Disease

    Breast Cancer

  • Test Drug

    DS-8201a

Participate Sites
6Sites

Recruiting5Sites

劉良智
China Medical University Hospital-Taipei

未分科

曾令民
Taipei Veterans General Hospital

Division of General Surgery

2019-02-01 - 2023-08-04

Phase III

A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

  • Condition/Disease

    Breast Cancer

  • Test Drug

    trastuzumab deruxtecan (T-DXd)

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2021-09-30 - 2030-04-04

Phase III

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)

  • Condition/Disease

    Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)

  • Test Drug

    BLINCYTO for Injection

Participate Sites
5Sites

Recruiting5Sites

2021-11-01 - 2024-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 12 13 14 15 16 17
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB